Navigation Links
Block its recycling system, and cancer kicks the can, according to new Penn study
Date:5/8/2012

PHILADELPHIA - All cells have the ability to recycle unwanted or damaged proteins and reuse the building blocks as food. But cancer cells have ramped up the system, called autophagy, and rely on it to escape damage in the face of chemotherapy and other treatments. Now, researchers at the Perelman School of Medicine; the Abramson Cancer Center; and the School of Arts and Sciences, at the University of Pennsylvania, have developed a potent new drug that clogs up the recycling machinery and kills tumor cells in mouse models.

Ravi K. Amaravadi, MD, assistant professor of Medicine, and colleagues showed previously that an old malaria drug, hydroxychloroquine, reduces autophagy in cancer cells and makes them more likely to die when exposed to chemotherapy. The strategy is currently being tested in clinical trials, and preliminary results are promising. The catch, though, is that it's not always possible to give patients a high enough dose of hydroxychloroquine to have an effect on their tumor cells.

Amaravadi teamed up with Jeffrey Winkler, PhD, the Merriam Professor of Chemistry, to design a series of more potent versions of chloroquine. They describe the design, chemical synthesis, and biological evaluation of a highly effective, new compound called Lys05, in the early edition of the Proceedings of the National Academy of Sciences this week.

Unlike hydroxychloroquine, which has little impact on tumor cells when used as a single agent, the new drug, called Lys05, slows tumor growth in animal models even in the absence of other anti-tumor therapies. What's more, the Lys05 dose that is toxic to cancer cells, which are addicted to recycling and rely on it much more heavily than healthy cells, has little or no effect on healthy cells.

"We see that Lys05 has anti-tumor activity at doses that are non-toxic for the animals," Amaravadi says. "This single-agent anti-tumor activity suggests this drug, or its derivative, may be even more effective in patients than hydroxychloroquine." Remarkably, however, when the investigators increase the dose of Lys05, some animals develop symptoms that mimic a known genetic deficiency in an autophagy gene, ATG16L1, which affects some patients with Crohn's disease . That similarity technically called a phenocopy clearly shows that Lys05 works by interfering with the recycling system in cells.

Lys05, and its companion compound Lys01, aren't quite ready for testing in patients, according to Amaravadi. Before that can happen, the molecules need to be optimized and undergo more toxicity testing in animals. Amaravadi and Winkler hope to team up with an industry partner for that portion of the project.

In the meantime, though, Amaravadi says the work illustrates just how important autophagy is to cancer cells, and provides an important new step for future therapies.


'/>"/>
Contact: Karen Kreeger
karen.kreeger@uphs.upenn.edu
215-349-5658
University of Pennsylvania School of Medicine
Source:Eurekalert

Related medicine news :

1. Penn study cautions use of drugs to block niacin flush
2. Red wine, fruit compound could help block fat cell formation
3. Novel drug in pill form safer than standard approach to treat blocked lung blood vessels
4. Judge Blocks Plan for Graphic Cigarette Warnings
5. Blocking telomerase kills cancer cells but provokes resistance, progression
6. Stents and surgery for blocked neck arteries are neck-and-neck as lasting stroke prevention
7. Plant flavonoid luteolin blocks cell signaling pathways in colon cancer cells
8. Drug-Coated Balloons Open Arteries Blocked by Narrowed Stents
9. Lipid blocks influenza infection
10. Judge Blocks FDA Plan for Graphic Cigarette Warnings
11. Inadequate supply of protein building blocks may explain pregnancy failures in bovine cloning experiments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... ... March 29, 2017 , ... ... without a referral to new patients from Burnaby, BC. Patients in need of ... mouth reconstruction services, can see the esteemed team at Wall Centre Dental. Drs. ...
(Date:3/29/2017)... ... 29, 2017 , ... Patients interested in receiving quick and ... Jamie Cameron, with or without a referral. The FASTBRACES system is valued for ... each patient’s case, treatment with the FASTBRACES system could be completed in 120 ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... (GRMA) is growing as it continues developing an ANSI-approved, consensus-based American National ... organization, which plans to publish the first ANSI-approved GMP standard for dietary ...
(Date:3/29/2017)... , ... March 29, 2017 , ... ... Library for documenting and diagramming network and data center assets and audio-video devices ... subscribers can request new equipment shapes for free and download shapes and stencils ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... wearing oral braces. "The rubber bands used in conjunction with my braces always ... decided to design a way to prevent this problem." The O.B.S. was the ...
Breaking Medicine News(10 mins):
(Date:3/30/2017)... March 30, 2017  Lannett Company, Inc. (NYSE: ... made a $25 million payment against its existing revolving ... combined with the $75 million payment we made earlier ... million in annualized cash interest expense, at current rates" ... Lannett.  "Our business is solid and we continue to ...
(Date:3/29/2017)... , Mar. 29, 2017 Research ... Neuromonitoring (IONM) Market Size & Forecast By Type (Insource IONM, ... 2025" report to their offering. ... The global Intraoperative Neuromonitoring ... 2025. The intraoperative neuromonitoring market is anticipated to witness significant ...
(Date:3/29/2017)... , March 29, 2017 Global intravenous (IV) iron ... billion by 2021, growing at a CAGR of 5%. ... by a doctor to treat anemia or other iron deficiencies. ... in the body. However, in some cases, oral administrations are ... and intravenous (IV) iron therapy comes into the picture. ...
Breaking Medicine Technology: